AVITA Medical, Inc. (RCEL) Misses Q1 EPS by 21c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
May 9, 2025 10:13 AM EDTCantor Fitzgerald analyst Ross Osborne reiterated an Overweight rating and $19.00 price target on Avita Medical Ltd. (NASDAQ: RCEL) following Q1 results, saying they would buy on today's weakness. The stock is down 22% in early trading.
The analyst commented, "We reiterate our Overweight rating and... More



